{"public_id":"cl_b12821fadcd22728840b045efe6c6ff5","status":"active","superseded_by_public_id":null,"corpus_id":2144044,"text":"PROSTVAC-VF comprises two recombinant viral vectors encoding transgenes for PSA and three immune costimulatory molecules (B7.1, ICAM-1, LFA-3), using a vaccinia-based vector for priming followed by six fowlpox-based vector boosts.","confidence":0.95,"paper":{"corpus_id":2144044,"title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.","url":"https://sah.borca.ai/papers/2144044"},"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_0225a28e8fa7002962581f8f588a4a8e","name":"PSA","description":"Prostate-specific antigen, the tumor antigen targeted by the immunotherapy vectors.","types":["antigen","biomarker"],"url":"https://sah.borca.ai/concepts/co_0225a28e8fa7002962581f8f588a4a8e"},{"public_id":"co_613df2f4ff6da0e9a777d84c9312173b","name":"immune costimulatory molecules","description":"B7.1, ICAM-1, and LFA-3 encoded in the viral vectors to enhance immune response.","types":["molecule","immunomodulator"],"url":"https://sah.borca.ai/concepts/co_613df2f4ff6da0e9a777d84c9312173b"},{"public_id":"co_6fb49d3cf80f19d07168123147806bb2","name":"PROSTVAC-VF","description":"A therapeutic poxviral-based PSA-targeted immunotherapy comprising vaccinia and fowlpox vectors encoding PSA and costimulatory molecules.","types":["immunotherapy","treatment"],"url":"https://sah.borca.ai/concepts/co_6fb49d3cf80f19d07168123147806bb2"},{"public_id":"co_fa66372187b36456a9ce68e9a2605764","name":"recombinant viral vectors","description":"Engineered vaccinia and fowlpox viruses used to deliver PSA and costimulatory molecule transgenes.","types":["vector","technology"],"url":"https://sah.borca.ai/concepts/co_fa66372187b36456a9ce68e9a2605764"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_b12821fadcd22728840b045efe6c6ff5"}